Fig. 7From: IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportationIllustration of IPO5 involvement in CRC. IPO5 interacts with the NLS sequence of RASAL2 leading to RASAL2 nuclear transposition, This preventing RASAL2 from functioning as a RAS signaling pathway suppressor in the cytoplasm. Thus resulting in RAS signal activation and CRC growth and metastasisBack to article page